ArticleACS omega2026
Deciphering the Anti-LUAD Mechanism of 4'-Demethyl-epipodophyllotoxin (4'-DMEP) via Machine Learning-Driven Target Identification and In Vitro Validation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
4'-Demethyl-epipodophyllotoxin (4'-DMEP) is a precursor of etoposide and has attracted much attention due to its significant antitumor activity. In order to elucidate the molecular mechanism of its inhibition of lung adenocarcinoma (LUAD), this study comprehensively used network pharmacology, machine learning, and molecular simulation technology, and verified it through cell experiments. A total of 171 drug targets and 11,439 disease targets were collected from the public database, and 131 intersection targets were obtained using the Venny tool. Then the 131 targets were visualized by PPI network. Subsequently, 38 significantly differentially expressed targets were screened and identified in the GEPIA database, from which 18 survival-related genes were further screened. GO functions related to mitotic cell cycle regulation and ERK1/ERK2 signaling, as well as KEGG pathways including gap junction and infection-related pathways, were also enriched. Four machine learning models screened five characteristic genes (SLC2A1, TOP2A, MIF, TLR4, and PLA2G1B). Molecular docking confirmed high-affinity interactions (binding energies ≤ -6.1 kcal/mol), a finding that was further validated by molecular dynamics simulation. In vitro experiments revealed that 4'-DMEP inhibited A549 cell proliferation by inducing cell cycle arrest and apoptosis, with significant changes in the expression of SLC2A1, TOP2A, and MIF. These findings not only clarify its molecular mechanism but also provide new ideas for the precise treatment of lung adenocarcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.